<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63469">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279641</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA3170-107</org_study_id>
    <nct_id>NCT02279641</nct_id>
  </id_info>
  <brief_title>RDEA3170 and Allopurinol Combination Study in Gout Subjects</brief_title>
  <official_title>A Phase 1b, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Allopurinol in Adult Male Subjects With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, randomized, open-label, drug-drug interaction study in adult male
      subjects with gout. It is designed to assess the pharmacokinetics (PK) and pharmacodynamics
      (PD) of RDEA3170 or allopurinol alone and in combination in the fed state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK profile of RDEA3170 and allopurinol/oxypurinol from plasma and urine (Cmax;Tmax;AUC;t1/2;Ae;CLR)</measure>
    <time_frame>22 days</time_frame>
    <description>Serial plasma PK samples.
PK endpoints in terms of maximum observed concentration (Cmax); time of occurrence of maximum observed concentration (Tmax); area under the plasma concentration time curve (AUC); apparent terminal half-life (t1/2); amount excreted in urine (Ae); renal clearance (CLR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD profile of RDEA3170 and allopurinol from serum and urine (serum urate concentration, urine uric acid excretion amount, renal clearance of uric acid, and fractional excretion of uric acid.)</measure>
    <time_frame>22 days</time_frame>
    <description>Serial serum PD samples at screening and on Days -1, 1, 7, 14, and 21.
Serial urine PD samples collected on Days -1, 1, 7, 8, 14 and 21.
PD endpoints in terms of serum urate concentration, urine uric acid excretion amount, renal clearance of uric acid, and fractional excretion of uric acid.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes in Laboratory, Electrocardiogram and Vital Signs Parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170 10 mg</intervention_name>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allopurinol 300 mg</intervention_name>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject meets one or more criteria for the diagnosis of gout as per the American
             Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary
             Gout.

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 45
             kg/m2.

          -  Subject has a Screening serum urate level ≥ 8 mg/dL and ≤ 10 mg/dL

          -  Subject is free of any clinically significant disease or medical condition, per the
             Investigator's judgment.

        Exclusion Criteria:

          -  Subject is unable to take colchicine for gout flare prophylaxis.

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has an estimated creatinine clearance &lt; 60 mL/min calculated by the
             Cockcroft-Gault formula using ideal body weight at Screening prior to Day -2.

          -  Subject is on unstable doses of chronic medications. Subjects taking medications for
             chronic medical conditions must be on stable doses during the course of the study,
             including the Screening period. Dose adjustments are allowed if deemed medically
             necessary by the investigator and following discussion with the medical monitor

          -  Chronic and stable doses of losartan, fenofibrate, guaifenesin, and sodium-glucose
             linked transporter-2 inhibitors are permitted if the dose is stable for at least 14
             days prior to study medication dosing.

          -  Subject is unable or unwilling to comply with the study requirements or has a
             situation or condition that, in the opinion of the Investigator, may interfere with
             participation in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Hall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 11, 2015</lastchanged_date>
  <firstreceived_date>October 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
